# Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01108913** · PHASE2 · COMPLETED · sponsor: **Revotar Biopharmaceuticals AG** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Bimosiamose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01108913
- **Lead sponsor:** Revotar Biopharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01108913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01108913, "Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01108913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*